Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lamivudine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 2/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | POLG | P54098 | 3/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamivudine SCHEMBL3444480 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL33979 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL12964486 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2305925 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2422788 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2240686 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL12996723 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL465678 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2806818 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL13006083 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13040 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432966-B1 | — | — | None | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4444311-B1 | GINSENOSIDES FOR TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTIONS | MENDEL UNIV IN BRNO (CZ) | 2026-05-06 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260091068-A1 | METHODS FOR TREATING AND PREVENTING DISEASES | Tets, Viktor Veniaminovich (US) | 2026-04-02 | — | — | US | claimed |
| US-20260083768-A1 | INFLAMMASOME INHIBITION FOR NEUROPROTECTION | AMBATI JAYAKRISHNA (US) | 2026-03-26 | — | — | US | claimed |
| EP-3534910-B1 | RIFAMPICIN DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | POP TEST ONCOLOGY LLC (US) | 2026-03-25 | — | — | EP | claimed |
| EP-0650362-A1 | ANTIVIRAL COMBINATIONS | GLAXO GROUP LIMITED (GB) | 1995-05-03 | — | — | EP | claimed |
| EP-0565549-B1 | USE OF 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF HEPATITIS B | IAF BIOCHEM INT (CA) | 1995-04-05 | — | — | EP | claimed |
| WO-1994005686-A1 | ANOMERISATION PROCESS | UNIVERSITY OF BIRMINGHAM (GB) | 1994-03-17 | — | — | WO | claimed |
| WO-1994002154-A1 | ANTIVIRAL COMBINATIONS | GLAXO GROUP LIMITED (GB) | 1994-02-03 | — | — | WO | claimed |
| EP-0517145-A1 | Crystalline oxathiolane derivatives | GLAXO GROUP LIMITED (GB) | 1992-12-09 | — | — | EP | claimed |
| WO-1992020344-A1 | ANTIVIRAL COMBINATIONS CONTAINING NUCLEOSIDE ANALOGS | GLAXO GROUP LIMITED (GB) | 1992-11-26 | — | — | WO | claimed |
| EP-0513917-A1 | Antiviral combinations containing nucleoside analogs | GLAXO GROUP LIMITED (GB) | 1992-11-19 | — | — | EP | claimed |
| WO-1992011852-A1 | USE OF 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES IN THE TREATMENT OF HEPATITIS B | BIOCHEM PHARMA INC. (CA) | 1992-07-23 | — | — | WO | claimed |
| EP-0494119-A1 | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B | BIOCHEM PHARMA INC. (CA) | 1992-07-08 | — | — | EP | claimed |
| WO-1991017159-A1 | 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES | IAF BIOCHEM INTERNATIONAL INC. (CA) | 1991-11-14 | — | — | WO | claimed |